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ABSTRACT
Inflammation is a complex defensive response activated after various harmful 
stimuli allowing the clearance of damaged cells and initiating healing and regenerative 
processes. Chronic, or pathological, inflammation is also one of the causes of neoplastic 
transformation and cancer development. MAP17 is a cargo protein that transports 
membrane proteins from the endoplasmic reticulum. Therefore, its overexpression 
may be linked to an excess of membrane proteins that may be recognized as an 
unwanted signal, triggering local inflammation. Therefore, we analyzed whether its 
overexpression is related to an inflammatory phenotype. In this work, we found a 
correlation between MAP17 expression and inflammatory phenotype in tumors and 
in other inflammatory diseases such as Crohn's disease, Barrett's esophagus, COPD 
or psoriasis. MAP17 expression correlated also with the markers of inflammation 
HLAs, BBS10, HERC2, ADNP and PYCARD. Furthermore, we found that MAP17 
expression directly regulates NFAT2 and IL-6 activation, inducing the differentiation 
of monocytes to dendritic cells and suggesting a causal role of MAP17 in inflammation. 
Immunohistochemistry confirms local inflammation, mainly CD45+ cells, at the site 
of expression of MAP17, at least in tumors, Crohn's and psoriasis. Therefore, our 
data indicates that the overexpression of the protein MAP17 plays important role in 
diseases involving chronic inflammation.
INTRODUCTION
Inflammation is a common defensive response 
that is activated after different harmful stimuli. It is a 
highly complex biological mechanism that allows the 
clearance of damaged cells and the removal of pathogens, 
initiating healing and regenerative processes [1, 2]. The 
inflammatory process activates signals that attract and 
activate inflammatory cells, such as macrophages, which 
generate and release cytokines and proinflammatory 
chemokines [3]. These molecules attract circulating 
leukocytes to the site of inflammation. After the 
elimination of harmful agents, this mechanism allows 
tissue repair to begin [4]. It is known that many cytokines 
activate regeneration-activating pathways such as those 
of YAP, Notch and Stat, which are also involved in stem 
cell activation [2, 5]. To end the inflammatory process, 
activated cells undergo apoptosis in a tightly regulated 
process that finishes after the phagocytosis of pathogens 
and cell debris [6]. However, when the inflammatory cells 
are incapable of eliminating the pathogen, inflammation 
may turn chronic, being characterized by a high level of 
leukocyte infiltration in damaged tissues. This chronic 
inflammatory condition contributed to the origin of many 
syndromes, including Crohn’s disease, lupus, psoriasis and 
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atherosclerosis. In addition, it has also been connected to 
Alzheimer’s disease and cardiovascular disease [7, 8].
This chronic, or pathological, inflammation is also 
one of the causes of neoplastic transformation and cancer 
development [9]. Indeed, approximately 25% of tumors 
have an important association with chronic inflammation 
derived from an infection, especially stomach cancer 
[10]. Persistent gastritis caused by Helicobacter pylori 
increases the risk of developing gastric tumor by 
75% [11]. In addition, infection with hepatitis B or C 
viruses increases the risk of hepatocellular carcinoma 
[12]. Further, chronic inflammation of the pancreas or 
prostate is commonly followed by the appearance of 
tumors in these organs [13]. Crohn’s disease is another 
example, increasing the risk of developing colorectal 
cancer by up to ten-fold [14]. All these tumors, derived 
from a chronic inflammatory condition, are characterized 
by the presence of immune cells and mediators of 
inflammation. Indeed, leukocytes can form up to 50% 
of total tumor mass [15]. The interaction between cancer 
cells and macrophages stimulates these cells to produce 
proinflammatory cytokines such as IL-8, thereby attracting 
additional inflammatory cells [16, 17]. This inflammatory 
microenvironment has been accepted as an essential 
component of all tumors [1, 16]. Recent efforts have been 
dedicated to understanding tumor-elicited inflammation, 
the inflammatory reaction that allows tumor development 
and is detected in many solid malignancies.
MAP17 (DD96, PDZKIP1) is a small, 
nonglycosylated membrane-associated protein that 
is located on the plasma membrane and in the Golgi 
apparatus [18–20]. MAP17 has an N-terminal hydrophobic 
region of 13 amino acids, a double transmembrane region, 
and a C-terminal region of 61 amino acids [21]. The last 
14 amino acids of the MAP17 C-terminal domain contain 
a PDZ-binding domain that allows the transport of this 
protein from the Golgi to the cell membrane. This domain 
allows its interaction with PDZK1 and its associated 
proteins, such as OCTN1, CFEX, URAT1 or NaPi-I/II [22, 
23]. Although its physiological role in proximal tubules is 
not fully known, MAP17 contributes, as a cargo protein, 
to the membrane localization of many transporters in the 
cellular membrane and stimulates specific Na-dependent 
transport of glucose in Xenopus oocytes and human tumor 
cells [23, 24].
MAP17 works as an oncogene, increasing 
tumorigenicity when it is overexpressed [25–29]. 
Tumor cells overexpressing MAP17 have proliferative 
advantage over cells not expressing MAP17 [25]. Also, 
its overexpression in cancer cells reduced the percentage 
of apoptotic cells and induced increased growth ratios 
in mice tumors [25, 30]. Furthermore, the ectopic 
MAP17 expression induced an increment in stem cell-
like properties, soft agar and tumorspheres assays, and 
increment in stem cell-like transcription [27, 30]. MAP17 
downregulation by specific shRNA in cells that naturally 
express high levels of MAP17, reduced tumorigenic and 
cancer stem cell-like properties of cancer cells [27, 30, 
31]. MAP17 overexpression activates Notch pathway 
due to direct interaction between MAP17 and NUMB 
in tumor cells [27]. This interaction is mediated by the 
13 last amino acids of MAP17, causing an increment in 
nuclear NICD and increased expression of Notch target 
genes, like HES1 or HES5 [27]. In addition, MAP17 levels 
are correlated with tumoral progression, being higher in 
late-stage or metastatic tumors regarding benign tumors 
or normal tissues. MAP17 overexpression has been found 
in advanced stages in ovarian, cervical, laryngeal and 
prostate tumors [26]. Thus, a high percentage of advanced 
tumors, from 50 to 90%, exhibits high levels of MAP17, 
being this expression correlated with an increment in 
dedifferentiation [23, 30, 32].
In normal conditions, MAP17 is expressed only 
in kidney proximal tubule cells, whereas the rest of the 
organism does not express this protein and does not have 
to cope with its effects. Therefore, its overexpression in 
other cell types may be linked to an excess of membrane 
proteins that may be recognized as an unwanted signal, 
triggering local inflammation. We therefore decided to 
analyze whether its overexpression could be related to 
an inflammatory phenotype. Because MAP17 is highly 
expressed in a large number of tumors, we looked 
first for a correlation between MAP17 expression and 
inflammation in tumors and then in other diseases related 
to chronic inflammation. We found a clear correlation 
between MAP17 expression and these inflammatory 
diseases. Furthermore, we found that MAP17 is causal in 
the inflammatory phenotype because MAP17 expression 
regulates the expression of important inflammation-related 
genes.
RESULTS
MAP17 expression correlates with inflammation 
in tumor samples
First, we analyzed a series of human cervix, 
breast and lung tumor samples [23, 33, 34], finding that 
MAP17-positive tumors usually correlated with higher 
levels of inflammatory infiltration (Figure 1A). Although 
the quantity of inflammatory cells infiltrating the tumor 
varied among the different tumor samples, it was clearly 
detected that, in these tumor types, MAP17 is significantly 
associated with inflammation (p < 0.05) (Figure 1B). 
These cells are mostly CD45+ (Figure 2) and its 
expression strongly correlated with MAP17 expression. To 
explore the different composition of these inflammatory 
populations we analyzed the CD4+ (T cells “helper”) 
and CD8+ (T cells “cytotoxic”) percentages, since this is 
relevant for efficacy of some antitumor therapies and have 
predictive value [35]. We have performed this study in 
breast, cervix, and lung tumor samples. We have observed 
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that, in general, CD4 and CD8 positive T cells can be 
observed infiltrating tumors (Supplementary Figures 1-3). 
Interestingly, in most of the samples, the percentage ratio 
of CD4+/CD8+ cells is >1. However, we have not found 
a correlation of the percentages of CD4 nor CD8 T cells 
with those of MAP17 expression (Supplementary Table 1).
To more deeply explore the correlation between 
MAP17 and inflammation, we next looked for genes that 
correlated with MAP17 in 4 tumor types: lung, cervical, 
breast and colorectal tumors (Supplementary Figure 4). To 
this end, we selected public datasets from transcriptomic 
analysis of these 4 tumor types (Supplementary Table 2). 
We first obtained the genes that correlated with MAP17 in 
all tumor types and then compared the individual tumor 
types to obtain a map of common genes correlating to 
MAP17 expression in various tumors. Thus, based on the 
bioinformatics analysis, we obtained four lists of genes 
negatively correlated with MAP17 (845, 1209, 1704, and 
1084 genes for lung, breast, colon, and cervical tumors, 
respectively) and another four lists of genes positively 
correlated with MAP17 (1473, 1292, 1653, and 1246 genes 
for lung, breast, colon, and cervical tumors, respectively). 
To find genes common to different tumors, we compared 
the lists of genes, identifying a substantial number of genes 
that appear in at least two of the selected tumors (Figure 
3A). Through these comparisons, we obtained 105 genes 
positively correlated with MAP17 and 17 genes negatively 
correlated with MAP17 in all tumor types considered 
(Supplementary Table 3). If we consider the presence of 
genes in at least 3 of the 4 different tumors, the number 
increases to 168 genes negatively and 449 genes positively 
correlated with MAP17 (Supplementary Tables 4 and 5).
Figure 1: Correlation of MAP17 expression with inflammation in human tumors. (A) Hematoxylin/eosin staining of 
histological slides of cervical, breast and lung cancer, showing a correlation of MAP17 levels with macrophage infiltration levels. (B) 
Quantification of the correlation of MAP17 expression with inflammation in human tumors. MAP17 expression was quantified in two 
independent sections of each sample, according to the intensity of the signal (0= no expression, to 3= very high expression), by double 
blind observation of two independent pathologists. Inflammatory infiltration was considered positive when the percentage of infliltrating 
cells was >5% of the total number of cells. Data include Student’s T test for statistical analysis of the data. * = p < 0.05; ** = p < 0.01; *** = 
p < 0.001.
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Gene ontology analysis of genes correlating with 
MAP17
To detect pathways that are significantly altered, 
we analyzed genes positively correlated with MAP17 
in at least 3 of the 4 tumors considered (Supplementary 
Table 5). Using enrichment analysis, we found that some 
of the altered pathways identified using the PANTHER 
database were correlated with membrane signaling and 
inflammation (for example, antigen processing and 
presentation of exogenous peptide antigen via MHC 
class I, TAP-independent, fold enrichment: 31.18; acute 
inflammatory response, fold enrichment: 8.85; positive 
regulation of protein secretion, fold enrichment: 4.68) 
(Figure 3B). In addition, we detected numerous proteins 
that are secreted or that can be found attached to the 
extracellular side of the cell membrane (Supplementary 
Table 6). In addition, most of the GO terms found were 
related to a secretory phenotype (Figure 3B). Three of 
the lowest p-values corresponded to defense response 
(p-value: 3.72x10-30), response to stress (2.48x10-23) and 
immune response (1.05x10-23). Further, inflammatory 
response is also one of the GO terms with a relatively 
low p-value (5.03x10-16). In addition, we found 
overrepresentation of the human leukocyte antigen (HLA) 
family (see Supplementary Table 3), with nine of its 
members (F, G, B, J, C, E, DMA, A and DRA) positively 
correlated with MAP17 in at least 15 of the total databases 
considered, as well as another 6 (DOB, DPA1, DMB, 
DQB1, DMB and DQB1) appearing in at least 10 of the 
analyzed databases (see Supplementary Figure 5). Genes 
of this family have been related to different inflammatory 
phenotypes, mainly due to changes in its expression levels 
[36–39].
PYCARD, CASP1 and CASP8, three of the genes 
positively correlated with MAP17, have been typically 
connected to inflammation as essential members of 
the inflammasome platform that triggers inflammatory 
Figure 2: Correlation of MAP17 expression with inflammation (CD45) in human samples of tumors of different origin. 
MAP17 and CD45 staining of serial sections of human samples of tumors of different origin. MAP17 staining in all samples showed high 
expression levels, correlated with the inflammatory marker CD45.
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response [40], appearing highly represented in the four 
types of tumors considered (see Supplementary Table 3). 
Other components, such as CASP5, appeared in three of 
the selected tumors, while NLRP1, NLRP3 or NLRC4, 
also components of inflammasome, appeared in one or 
two of the selected databases. Interleukin-1β (IL-1B), a 
proinflammatory cytokine that is produced as an inactive 
cytoplasmic precursor and is cut by caspase-1 (CASP1) 
[40], also appeared in all tumors. Not only does IL-1B 
appear positively correlated with MAP17 in all tumors, 
other interleukins including IL-15, IL-18, IL-1A, IL-32 
and IL-7 and interleukin receptors including IL-10RB, 
IL-17RC and IL-2RG appear in at least three of the 
tumor types (Supplementary Table 5). All these elements 
have been correlated with an increase in inflammation 
[41, 42].
Figure 3: (A) Venn diagrams of the significant genes found negatively and positively correlated with MAP17 in lung, breast, colon and 
cervical tumors, showing that, for negative correlations, 17 genes appears equally negatively correlated and 105 genes positively correlated 
with MAP17 in the four tumor types considered (p-value < 0. 05). (B) GO Biological terms related to inflammation that appear with genes 
positively correlated with MAP17 in at least three of the four types of tumors.
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Regarding negative correlations, we found no 
prominent pathways connected to MAP17, although it is 
noteworthy that one of the GO terms was “developmental 
process”, suggesting an inhibition of cell differentiation, 
a feature of cancer cells (see Supplementary Table 7). 
The analysis of common genes allowed us to find another 
GO term related to differentiation, “Anatomical structure 
development”. In addition, we found that “chromosome 
organization” was negatively correlated with MAP17, and 
this process may be related to the chromosome instability 
of cancer cells.
Inflammatory response is commonly positively 
correlated with MAP17 in tumoral samples. To determine 
whether our results were a common feature in other 
tumors (ovary, thyroid and prostate, maintaining breast 
as a positive control), connecting MAP17 with a higher 
inflammation phenotype, we selected 3 genes for each 
type of correlation with MAP17: HLA-A, HLA-B and 
HLA-C for positive correlations and BBS10, HERC2 and 
ADNP for negative correlations. HLAs positive correlation 
to inflammation have been largely described [43]. BBS10 
(Bardet-Biedl Syndrome 10) missense mutations have 
been correlated with higher inflammatory markers [44]. 
ADNP (Activity-Dependent NeuroProtector) expression 
has been connected with a reduction on the expression 
of pro-inflammatory cytokines [45]. HERC2 (HECT and 
RLD domain containing protein 2 ortholog) is a probable 
E3 ubiquitin-protein ligase. Comparative genetic analysis 
of inflammatory bowel disease and type 1 diabetes 
implicates HERC2 loci [46]. HERC2 has been genetically 
associated with Crohn’s disease [47], sarcoidosis and its 
acute and chronic subphenotypes [48]. We analyzed the 
behavior of all these genes in different tumor samples and 
compared them to that of MAP17. We identified significant 
increases in the expression of HLA-A, HLA-B and HLA-C 
in the four tumor types considered, whereas BBS10, 
HERC2 and ADNP showed a clear tendency toward 
decreased expression when MAP17 is overexpressed 
(Figure 4). The two controls, ACTB (actin) and TUBA1B 
(tubulin), did not show significant differences in any of the 
databases selected (Figure 4), confirming the specificity 
of our data. PYCARD and CASP1, two of the elements 
of the inflammasome platform implicated in the IL-1B 
maturation process, appear also significantly increased, 
correlating with high levels of MAP17 (Supplementary 
Figure 6). These results showed that MAP17 
overexpression can be connected with an inflammatory 
phenotype, and we therefore decided to analyze whether 
this overexpression acts as a marker of inflammation or 
may be an indirect cause of it.
MAP17 expression regulates inflammatory genes
First, we generated cells in which MAP17 was 
overexpressed, such as in breast tumor cells T47D, or 
in the sarcoma cells AW [49]. Previously, we showed 
that MAP17 overexpression in these cells induces an 
increment in tumorigenic properties [50, 51]. Here, we 
detected that MAP17 overexpression caused an increased 
expression of HLA genes, while significantly decreasing 
(p < 0.05) the expression of BBS10, HERC2 and ADNP 
(Figure 5A). Furthermore, using specifically targeted 
shRNA, we downregulated MAP17 in Calu3 lung tumor 
cells, which endogenously express high levels of MAP17 
(Figure 5A). In these cells, MAP17 downregulation 
causes a clear reduction in the expression of HLAs while 
increasing BBS10 expression. Although no increase 
in HERC2 or ADNP was observed in Calu3 cells, a 
decrease in PYCARD was detected when MAP17 was 
downregulated (Supplementary Figure 7). Therefore, we 
concluded that MAP17 expression regulates the expression 
of inflammation-related genes, suggesting a causal effect 
of MAP17 in this phenotype (Figure 5A).
In order to determine the mechanism induced 
by MAP17 overexpression in tumor cells, we looked 
for NFAT2 and IL-6 expression, known attractant of 
inflammasome. NFAT2 belongs to a family of transcription 
factors that modulate the inflammatory response [52], 
while IL-6 has been connected to chronic inflammation, 
being produced at the site of inflammatory response [53]. 
In all the tumor cells overexpressing MAP17 (Figure 
5B), we detected a clear increment in the expression of 
IL-6, while NFAT2 was clearly increased in HeLa cells 
with small changes in the other considered cell models, 
showing that MAP17 has a real role as an inflammatory 
inducer (Figure 5C). However, this increment might not 
be related with an increment in gene transcription, so we 
analyzed NFAT2 expression in AW cells, finding a higher 
nuclear/cytoplasm NFAT2 ratio in cells overexpressing 
MAP17 (Figure 5D).
Finally we tested whether the overexpression of 
MAP17 liberates proinflammatory inducers to the media 
and the ability of this media to induce the differentiation 
of monocytes to macrophages. To this end we cultured 
the U937 monocyte cell line in conditioned media (1:1) 
from AW and AA cells overexpressing MAP17, in addition 
to Calu3 cells with downregulated MAP17 expression. 
Although we tested U937 with T47D conditioned 
media, the number of derived attached cells was so low 
72 hours after the beginning of the experiment that we 
could not find any significant differences, so we used AA 
cells, a previously characterized cell line where MAP17 
overexpression also increased tumorigenic properties 
[50]. We expect this experiment reconstitutes in vitro the 
physiological conditions found at MAP17-positive tumor 
site. We found that part of the U937 monocyte cell line 
attached to the plate, showing cells exposed to MAP17-
conditioned media a significantly higher percentage of 
dendritic cells (Figure 5E, 5F), confirming our hypothesis 
of the relevant causal role of MAP17 in inflammation. 
In fact, IL-6 has been previously connected to monocyte 
differentiation to dendritic cells [54].
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MAP17 overexpression is a common feature in 
chronic inflammatory diseases
After analyzing the connection between MAP17 
and the inflammatory profile in tumoral samples, we 
wondered whether this profile was limited to cancer 
or could be considered a general effect. Therefore, we 
analyzed this gene profile (MAP17, HLA-A, HLA-B, 
HLA-C, BBS10, HERC2 and ADNP) in non-tumoral 
samples of inflammatory syndromes, using chronic 
obstructive pulmonary disease (COPD), lung fibrosis 
and Barrett’s esophagus to represent the inflammatory 
state and using both normal macrophages and epithelia 
to determine basal levels. We observed a similar pattern, 
with a high expression level of MAP17 in inflammatory 
diseases compared to normal epithelial cells, connected 
to increased expression of HLA-B and HLA-J, members 
of the HLA family found in our screening, and 
downregulation of BBS10, HERC2 and ADNP (Figure 
6A). In addition, we also evaluated Crohn’s disease and 
Figure 4: Expression of HLA-A, HLA-B, HLA-C, BBS10, HERC2 and ADNP in breast, thyroid and ovarian cancer 
samples, grouped by differential expression levels of MAP17, obtained through RNA normalization of public 
transcriptomic arrays, as described in Methods, Bioinformatic analysis section. Once grouped, Student’s T test for statistical 
analysis of the data was applied. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. All significant differences found in ovary, thyroid and prostate 
tumors showed the same correlation with MAP17 that the previously found for breast, colon, cervix and lung tumors. In the case of non-
significant differences, the tendency of the samples points, also, the same direction.
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three colon inflammation databases, using normal colon as 
a control. Again, we found increased expression of HLA 
genes, correlating with increased MAP17, while BBS10, 
HERC2 and ADNP generally showed reduced expression 
(Figure 6B).
To increase the accuracy of our data, we selected 
a large database of ileal Crohn’s disease (GSE57945), 
a chronic inflammatory disease with no known origin, 
to analyze MAP17 expression and its correlation to the 
six selected inflammatory genes. We found positive 
correlations between MAP17 and the three HLA genes 
and negative correlations between MAP17 and BBS10, 
HERC2 and ADNP (Figure 7A). Indeed, a heatmap of 
the individual datasets using MAP17 and the selected six 
genes as classifiers clearly showed the correlation with the 
six inflammatory genes (Figure 7B).
Lupus and psoriasis are another two inflammatory-
related diseases, in this case affecting skin although of 
very different inflammatory physiology. To analyze the 
possible connection between MAP17 and these diseases, 
we selected three databases corresponding to systemic 
lupus erythematosus (GSE13887), a mixed database with 
discoid lupus erythematosus and psoriasis (GSE52471), 
and a database for a lupus model in mice (GSE20735). 
In all of them, we observed a clear increase in MAP17 
expression (Figure 7C, 7D, 7E). Considering both 
the first database and lupus patients from the second 
database (SLE from Figure 7C and DL from Figure 7D), 
Figure 5: (A) mRNAexpression levels of HLA-A, HLA-B, HLA-C, BBS10, HERC2 and ADNP in cancer cells transfected for 
overexpression of MAP17 (T47D, AW) or knockdown of MAP17 with specific shRNA (Calu3). (B) MAP17 expression in human cells 
transfected to induce its overexpression (T47D, AW, HeLa) or knockdown (Calu3). (C) WB of NFAT2 and IL-6, pro-inflammatory proteins, 
in cancer cells that overexpress MAP17 (T47D, AW, HeLa) or with its expression downregulated (Calu3). IL-6 is clearly overexpressed 
in cell lines with higher MAP17 levels, while NFAT2 appears also with higher levels in the cells that overexpress MAP17. (D) NFAT2 
nuclear proportion is increased due to MAP17 overexpression. Left) nuclear/cytoplasm relation in AW cells transfected with EV or MAP17 
overexpressing vector, according to the fluorescence microscopy images obtained of NFAT2 expression. Right) Fluorescence microscopy 
of AW EV or AW MAP17 cells. The latter exhibits higher nuclear levels of NFAT2 (E) U937 cells attached to the plate, after being exposed 
to conditioned cell media (See Methods). Some cells showed the typical form of differentiated dendritic cells (black arrows). (F) Percentage 
of attached U937 cells for different conditioned media. The percentage of cells with dendritic morphology is higher for cells with higher 
MAP17 levels. All experiments were repeated a minimum of three independent times in triplicate. All figures include Student’s T test for 
statistical analysis of the data. * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
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we observed significant differences in almost all of our 
selected genes when we separated individuals into two 
groups: low and high MAP17 expression. In addition, in 
a mouse model that simulates lupus progression, animals 
experienced an increased expression of MAP17 connected 
with a decrease in RFX3, a negative regulator of HLAs, 
and decreases in HERC2 and ADNP (Figure 7E). Finally, 
a similar profile was found in psoriasis, with an increase 
in MAP17 correlating to increased expression of HLAs 
and decreased expression of BBS10, HERC2 and ADNP 
(Ps from Figure 7D).
To finally confirm these data, we selected 20 
samples of human Crohn’s disease and 20 samples of 
human psoriasis and tested the expression of MAP17 in 
these tissues. We found that 20 out of 20 psoriasis samples 
showed a clear presence of MAP17 in the epithelial 
parenchyma. These MAP17-positive cells appear 
surrounded by inflammatory cells (Figure 8). Similar data 
were obtained for samples from human Crohn’s disease; 
75% of the samples analyzed showed clear staining 
for MAP17 in epithelial cells that were surrounded by 
inflammation (Figure 8). In all positive cases, we could 
observe a clear plasma membrane localization of MAP17. 
We also could observe a clear staining for CD45 and 
CD68 markers, two previously described specific surface 
markers of inflammation (Figure 8 and Supplementary 
Figures 8, 9 and 10). CD45, known also as common 
leukocyte antigen or receptor-type tyrosine-protein 
phosphatase C, is a very abundant leukocyte cell surface, 
being its expression restricted to haematopoietic cells [55]. 
CD68, a selective marker for monocytes and macrophages, 
have been previously connected to inflammatory diseases, 
like inflammatory bowel disease or Crohn’s disease [56, 
57].
Thus, our data confirm that the expression of the 
cargo protein MAP17 is a determinant of the induction of 
chronic inflammation and may be involved in the initiation 
of illnesses such as Crohn’s disease, psoriasis, COPD and 
cancer.
DISCUSSION
MAP17 has been found to be overexpressed in 
more than 50% of all tumors, also showing increased 
Figure 6: (A) Normalized expression levels of MAP17 (PDZK1IP1), HLA-A, HLA-B, HLA-C, BBS10, HERC2 and ADNP in inflammatory 
diseases. NE: Normal Epithelium (Shelhamer database), NM: Normal Macrophage (Salazar database), MEB: Mixed Barrett’s Esophagus, 
DC: COPD (Tiley database), DLF: Lung Fibrosis (Meltzer database). (B) Normalized expression levels of MAP17, HLA-B, BBS10, HERC2 
and ADNP in colon. NC: Normal Colon (Vivier database), DC1: Diseased colon (Sleiman database), DC2: Diseased colon (Salas database), 
DC3: Diseased colon (Seidelin database), Cr: Disease Crohn’s disease (Arijs database). In both cases, the differences in the expression 
of the considered genes between normal and inflammatory samples are usually in the same direction that the previously found in tumoral 
samples. Data were obtained through MegaSampler, included in R2 server and analyzed using the MAS5.0 algorithm and are presented as 
the log2 transform.
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expression during tumor progression [26, 58, 59]. 
This protein, through its PDZ-binding domain, acts as 
a protein carrier from the Golgi apparatus to the cell 
membrane. However, according to our results, MAP17 
not only triggers the attraction of inflammatory cells by 
increasing protein membrane loading but also modifies the 
expression of genes connected to inflammation, showing 
a clear induction of the inflammatory profile. First, 
MAP17 expression correlated with chronic inflammatory 
diseases. Second, within the list of genes related to 
MAP17 expression, there are numerous genes involved 
in the inflammasome; therefore, inflammatory pathway-
related genes positively correlated with MAP17. Finally, 
MAP17 expression appeared to regulate the expression 
of inflammation-related genes, through induction of 
genes like NFAT2 and IL-6. Therefore, we suggest that 
the expression of MAP17 triggers chronic inflammation 
in various inflammatory diseases such as Crohn’s disease, 
Barret’s esophagus, lupus, psoriasis and COPD. Because 
MAP17 appears highly correlated with the infiltration 
of inflammatory cells in cancer, we can also suggest 
that MAP17 expression triggers chronic inflammation 
in many tumors. However, MAP17 is clearly not the 
only determinant of chronic inflammation because some 
samples of tumors, lupus, COPD and other inflammatory 
diseases showed no expression of MAP17.
We have shown that, in tumors, MAP17 activates 
components related to the inflammatory phenotype such 
as HLA molecules, proteins belonging to the major 
histocompatibility complex (MHC) family that can be 
induced in tumor cells as a result of local inflammation. 
HLA proteins are involved in antigen presentation 
to lymphocytes through a mechanism that involves 
proteasomal degradation of the antigen, its transport 
to the endoplasmic reticulum and its externalization 
to the plasma membrane [60, 61]. It has been reported 
that tumoral cells can upregulate HLA-A, HLA-B and 
HLA-C expression, decreasing the level of macrophage 
activation [62, 63]. In addition, it has been reported that 
the presence of these proteins in the plasma membrane 
Figure 7: Correlation of MAP17 with proinflammatory molecules in ileal Crohn’s disease. (A) Correlation of MAP17 
(PDZK1IP1) with HLA-A, HLA-B, HLA-C, BBS10, HERC2 and ADNP in ileal Crohn’s disease, showing that MAP17 is positively correlated 
with HLA-C, HLA-A and HLA-B, and negatively correlated with BBS10, HERC2 and ADNP. (B) Heatmap of MAP17 (PDZK1IP1) with 
HLA-A, HLA-B, HLA-C, BBS10, HERC2 and ADNP in ileal Crohn’s disease, showing that, in general, MAP17 is associated with low levels 
of BBS10, HERC2 and ADNP and with high levels of HLAs. (C, D and E) Expression levels of MAP17, HLA-A, HLA-B, HLA-C, BBS10, 
HERC2 and ADNP in lupus and psoriasis. (C) C: control (n=10); SLE: systemic lupus erythematosus (n=10); (D) C: control (n=13), DL: 
discoid lupus (n=7); Ps: psoriasis (n=18); (E) E: 6-8 week (n=3) TC RB+/CD4++/B220- cells; L: 16-24 week (n=9) TC Rb+/CD4+/B220-/
CD44+ cells. Disease progression showed a progresive increment in MAP17 expression levels. Data include Student’s T test for statistical 
analysis of the data. * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
Oncotarget98590www.impactjournals.com/oncotarget
inhibits the cytolytic function of natural killer cells [64, 
65]. This inhibition of the activation of macrophages 
and natural killer cells occurs through the interaction 
of HLA proteins with the receptors LILR (Leukocyte 
immunoglobulin-like receptor) and KIR (Killer cell 
immunoglobulin-like receptor), negatively regulating 
their function [62]. MAP17, which is overexpressed 
in almost 50% of advanced carcinomas, increases its 
expression with the malignance of the tumor [32]. It has 
been previously shown that MAP17 is overexpressed 
in tumor cells due to progressive demethylation of its 
promoter [26, 66]. As a consequence of increased MAP17 
levels, cell tumorigenic properties are increased, due to 
Notch pathway activation through NUMB abduction [50]. 
It has been shown that, through Notch pathway activation, 
NFAT pathway and IL-6 transcription are activated 
[67, 68]. In fact, we found NFAT2 positively correlated 
with MAP17 in five of our considered datasets (data not 
shown), and NFAT2 protein levels are significantly higher 
in cells overexpressing MAP17, being preferentially 
translocated to nuclei. Correlating with what has been 
previously shown [69], IL-6 levels are also increased 
by MAP17 expression. Addition of two proteins well 
connected to inflammatory response, IL-6 and Interferon-γ 
(IFNG), to cells induced expression of both HLA class 
I and class II [70–72]. In fact, IFNG receptors IFNGR1 
and IFNGR2 appear overrepresented as genes positively 
correlated with MAP17 (Supplementary Tables 3 and 
5). Here, we have shown that MAP17 directly regulates 
HLA expression in tumor cells, and we have correlated 
MAP17 overexpression in different tumors with higher 
levels of these MHC genes. In addition, we found that, 
Figure 8: Correlation of MAP17 expression with inflammation in human samples of Crohn’s disease and psoriasis. 
MAP17, CD45 and CD68 staining of histological slides of human samples of psoriasis and Crohn’s disease. MAP17 staining in both 
inflammatory diseases showed high expression levels, correlated with the inflammatory markers CD45 and CD68.
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when MAP17 is overexpressed in tumoral tissues, 
there is an increase in macrophage infiltration, a clear 
marker of inflammation. Now, we can hypothesize that 
these macrophages should be inhibited due to the HLA 
expression guided by MAP17.
On the other hand, the large inflammatory response 
is a common feature of many tumors. This inflammatory 
response may not be the origin but act synergistically 
during the process of tumorigenesis. It is possible 
that the expression of the MAP17 proteins acts as an 
immune chemoattractant, and this immune presence 
then collaborates with neoplastic alterations. Enhanced 
inflammation surrounding target tissues could be a tumor 
promotion mechanism led by MAP17 deregulation 
controlling the development of hematopoietic cells that 
regulate inflammation, and mediate the responses of 
target cells to inflammatory cytokines. Mechanistically, 
high MAP17 levels increase the recruitment of tumor/
inflammation associated macrophages, MDSCs, mast 
cells, and neutrophils to the target tissue, by increasing 
IL-6 locally and probably other cytokines or chemokines. 
It is possible that the increase in these cytokines in the 
extracellular media surrounding tumor cells might 
promote tumorigenesis by activating the NFkB and/or 
STAT3 pathways [73].
Therefore, it is possible that MAP17-positive tumors 
may be a target for immunotherapy. New antitumor 
therapy focused on inhibiting these inhibitory signals 
may be useful for targeting these MAP17-positive tumors. 
However, this is a preliminary hypothesis that must be 
experimentally tested.
Although we have described that MAP17 is 
commonly overexpressed in advanced tumors, its 
overexpression induces a higher level of tumorigenesis 
and increases ROS. The analysis of the correlation of 
MAP17 expression levels with survival in different tumors 
is complex. MAP17 levels can be considered as a marker 
of good prognosis in some tumors as cervix, treated with 
cisplatin and radiotherapy, strongly inducers of ROS [23]. 
However, in other tumors such as sarcoma treated with 
doxorubicin, MAP17 is a marker of worse prognosis [29]. 
Our group has also shown that cells with high levels of 
MAP17 are more sensitive to bortezomib treatment due 
to higher ROS production [74]. In addition, multiple 
myeloma patients, treated with bortezomib, showed higher 
levels of MAP17 associated to better prognosis [74].
In the present work we also found MAP17-positive 
tumors surrounded by CD4+ and CD8+ T cells in the tumor 
microenvironment. Since these cells are also involved in 
the overall response to treatments, the relative levels of 
these cells have been reported as good predictors of the 
patient survival in different tumors [35, 75]. Therefore, 
the survival observed in MAP17-positive patients may be 
a complex factor depending on the production of ROS and 
also related to the CD4/CD8 ratio of cells in the tumor 
microenvironment.
Nonetheless, the presence of immune cells in 
tumors constitutes positive feedback for oxidative stress, 
stimulating DNA damage and subsequent genome 
instability [1, 76]. However, leukocytes and their failed 
cell clearance must not be seen as a cause of tumor 
progression. Indeed, the appearance of mutations in 
damaged cells can also activate the immune response. 
Altogether, the activation of the inflammatory response 
by genetic alterations induces the appearance of a higher 
number of mutations [77]. However, it must be noted that 
not all chronic inflammatory diseases increase the risk 
of developing tumors. Indeed, some such diseases, like 
psoriasis, can reduce the probability of cancer [78]. In 
this regard, it is interesting to remark that when MAP17 
is overexpressed in naïve cells, these undergo senescence 
[33], therefore affecting the ration of tumor initiation. 
How MAP17 expression may affect different tissues needs 
to be thoroughly studied.
In addition to the expression profile of MAP17 in 
tumoral samples, we also analyzed the same profile of 
MAP17-related genes in up to seven inflammatory diseases 
(COPD, lung fibrosis, Barrett’s esophagus, Crohn’s 
disease, colon inflammation, lupus and psoriasis). Most 
of the genes that we found correlated with MAP17 (both 
positively and negatively) showed the same pattern in all 
of these diseases. We have recently shown that MAP17 
overexpression rendered tumor cells more susceptible to 
treatment with bortezomib, a proteasome inhibitor [29, 
74]. In fact, it has been reported that bortezomib decreases 
the inflammatory response [79–81]. Thus, MAP17 may 
be useful as a biomarker of susceptibility to proteasome 
inhibitors for the treatment of chronic inflammatory 
diseases.
MATERIALS AND METHODS
All methods were performed in accordance with 
the relevant guidelines and regulations of the Institute 
for Biomedical Research of Seville (IBIS) and University 
Hospital Virgen del Rocio (HUVR). All conform to the 
provisions of the Declaration of Helsinki (as revised in 
Edinburgh 2000). Only remnant tissue was used for 
the project. All patients declare informed consent. The 
protocol was approved by the local ethics committee of 
the HUVR (CEI 2013/PI002). We report the availability 
of the ‘data set’ necessary to interpret, replicate and build 
on the findings reported in the paper. All of them are based 
on already public database conveniently described. All 
other reagents will be available to scientist upon request 
to validate these results.
Cell lines and transfection
The T47D, HeLa, Calu3 and U937 cell lines 
were obtained from the European Collection of Animal 
Cell Cultures (ECACC) commercial repository at the 
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beginning of the study (2012). No further authentication 
was performed by the authors. The CNIO AA and AW 
sarcoma cell lines have been generated in our lab and 
previously described [82]. Cell lines were transfected 
with pBABE to overexpress MAP17 (T47D, HeLa, AA 
and AW) or shRNA targeting MAP17 (Calu3) and were 
selected with 1 μg mL-1 of puromycin.
Analysis of gene transcription
Total RNA was purified using the ReliaPrepTM 
RNA Tissue Miniprep System (Promega, Fitchburg, 
WI, USA) according to the manufacturer's instructions. 
Reverse transcription was performed with 3 μg of mRNA 
using the High-Capacity cDNA Reverse Transcription 
Kit (Life Technologies) according to the manufacturer’s 
recommendations. To detect changes in gene expression, 
we used the following probes, all from Life Technologies: 
MAP17 (Hs00906696_m1), HLA-A (Hs01058806_g1), 
HLA-B (Hs00818803_g1), HLA-C (Hs00740298_g1), 
BBS10 (Hs00379769_g1), HERC2 (Hs00190589_m1), 
ADNP (Hs00209721_m1), PYCARD (Hs01547324_gH) 
and GAPDH (Hs03929097_g1). Quantitative PCR was 
performed and normalized as previously described [51]. At 
least three independent experiments were performed for each 
of the analyzed genes. Student’s t-test was applied for each 
pair of samples, with a significance threshold of p < 0.05.
Immunohistochemistry
IHCh analyses were previously described at 
[83–85]. The primary antibodies CD45 (NB110-93609, 
Novus Biologicals), CD68 (MCD497, Bio-Rad), CD4 
(SP35, Roche) and CD8 (SP57, Roche) were incubated 
overnight at 4ºC as previously described in [23, 33, 83]. 
Primary antibodies anti-MP17 was used at 1:4 dilution, as 
previously described [23]. A secondary antibody anti-goat 
(ab97100) for MAP17 was used. For CD45, CD68, CD4 
and CD8 antibodies, the anti-rabbit (JI-111-035-003) was 
applied and revealed using substrate buffer and chromogen 
(Envision, Flex DAKO). The tissues were counterstained 
with hematoxylin (DAKO).
Dendritic differentiation
Conditioned media from AW, Calu3 and AA cells 
were filtrated using a 0.45 μm pore size. 104 U937 cells 
non-adherent cells were cultured for 72 hours in 6-well 
plates with 50% conditioned media, plus 50% RPMI. 
The plates were washed twice with PBS and fixed using 
glutaraldehyde 0.5%. After that, cells were stained with 
1% crystal violet, washed twice with PBS and dried.
Protein extraction and WB analysis
Western Blot analysis were obtained as described 
previously [51]. We used antibodies against IL-6 (Cell 
Signaling, #12912, 1:1000 dilution), NFAT2 (Cell 
Signaling, #8032, 1:1000 dilution) and α-Tubulin (Sigma, 
T9026, 1:10000 dilution). Horseradish peroxidase–labeled 
rabbit anti-mouse (Abcam, ab97046, 1:5000 dilution) 
and goat anti-rabbit (Abcam, ab97051, 1:5000 dilution) 
secondary antibodies were used.
NFAT2 quantification
AW cells were cultured, fixed and permeabilized 
as previously described [50]. Then, anti-NFAT2 (Cell 
Signaling, #8032) were added to cells in 1 mL of PBS, 
0.1% Triton X-100, 3% BSA at a 1:1000 dilution and 
incubated overnight at 4ºC with gentle stirring. After 
that, coverslips were washed four times with PBS, 1% 
Triton X-100 for 5 minutes each time, with a final wash 
with PBS for 5 minutes. For NFAT2 quantification 
immunofluorescence assay, Alexa Fluor goat anti-rabbit 
IgG (A-11008, Life Technologies) was added at a 1:250 
dilution to the cells in 1 mL of PBS, 0.1% Triton X-100, 
3% BSA and incubated in dark at room temperature for 
2 hours with gentle stirring. Cells were then washed 
three times (5 minutes each) with PBS, 0.1% Triton 
X-100. Finally, coverslips were mounted on a slide with 
a drop of mounting solution (Prolong Gold Antifade, 
Life Technologies) and dried. NFAT2 images were 
acquired in an Olympus BX61 fluorescence microscope. 
Nuclear NFAT2 was quantified using ImageJ software 
and expressed as the fluorescence in nuclei relative to the 
normalized cytoplasm fluorescence.
Bioinformatics analysis
To find genes correlated with MAP17, we selected 
5 databases for cervical cancer, 6 databases for lung 
cancer, 19 databases for breast cancer and 10 databases 
for colon cancer (see Supplementary Table 2). All of these 
databases are freely accessible through the R2 webpage 
(R2: Genomics Analysis and Visualization Platform 
(http://r2.amc.nl).
Correlations with MAP17
We looked for correlations with MAP17 
(PDZK1IP1, 219630_at), using an R-value lower than 
0.05 in order to find significant differences. To find gene 
expression correlations, we used probe 219630_at, which 
corresponds to MAP17, for all Affymetrix datasets. For the 
TCGA and Budinska datasets, we used a unique probe for 
the MAP17 gene.
From the list of correlated genes, we separated genes 
positively correlated with MAP17 from genes negatively 
correlated with MAP17, generating two gene lists for each 
database. Next, we looked for genes highly represented 
among the different datasets. Thus, we established a 
cutoff for each gene of appearing at least in two different 
databases in cervical cancer, three different databases in 
lung cancer, and five different databases each in breast 
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and colon cancer. We thereby generated four groups of 
genes commonly negatively or positively correlated with 
MAP17. To generate a Venn diagram to find common 
genes correlated with MAP17 for all tumors, we used 
the tool Venny (Oliveros, J.C. (2007-2015) Venny. An 
interactive tool for comparing lists with Venn's diagrams. 
http://bioinfogp.cnb.csic.es/tools/venny/index.html).
Gene ontology (GO) analysis
To identify which pathways or Gene Ontology (GO) 
terms were connected to genes positively or negatively 
correlated with MAP17, we used enrichment analysis 
from the Gene Ontology consortium webpage (http://
geneontology.org/page/go-enrichment-analysis). To find 
the subcellular locations of the proteins encoded by the 
genes identified as correlated with MAP17, we used the 
UniProt server (http://www.uniprot.org/).
The expression of individual genes in different 
databases was analyzed using MegaSampler software, 
included in the R2 server. For that purpose, we used 
the following probes: MAP17 (219630_at), HLA-A 
(213932_x_at), HLA-B (204140_x_at), HLA-C 
(216526_x_at), BBS10 (219487_at), HERC2 (217902_s_
at) and ADNP (226426_at). As controls for lung 
inflammatory diseases, we used the normal datasets 
Shelhamer (GSE39061) [86] and Salazar (GSE2125) 
[87], while datasets from Wang (Mixed Barrett’s 
Esophagus, GSE26886) [88], Tiley (COPD, GSE43939) 
[89] and Meltzer (Lung Fibrosis, GSE24206) [90] were 
used to analyze the gene profile in disease status. To 
analyze the expression of the same set of six genes in 
colon inflammatory diseases, we selected Vivier dataset 
(GSE41469) [91] as a control, along with one database 
for Crohn’s Disease (Arijs, GSE16879) [92] and three 
databases for Colon Inflammation (Seidelin, GSE9452 
[93]; Sleiman, GSE10616 [94] and Salas, GSE38713 
[95]) were used for disease state. In this case, we used a 
probe for HLA-J (217436_x_at), another gene positively 
correlated with MAP17. All data were normalized 
using the MAS5.0 algorithm and are shown as the log2 
transform, performed automatically by R2 software.
R bioconductor analysis.
To examine whether this inflammatory profile is 
connected to MAP17 overexpression in other tumors, we 
selected another four cancer databases (GSE9574, breast 
cancer; GSE6008, ovarian cancer; GSE27155, thyroid 
cancer; GSE55945, prostate cancer). For this analysis, 
we did not consider non-tumoral samples. For the ovarian 
cancer dataset, we selected serous adenocarcinoma 
samples, while for thyroid cancer, we selected follicular 
variant thyroid gland papillary carcinoma samples. Each 
whole dataset was normalized using the RMA algorithm 
in Bioconductor, and tumoral samples were separated 
into two groups: low or high expression of MAP17. To 
analyze the expression of the genes identified above, 
we used the same probes, with the exception of HLA-B 
(208729_x_at) and ADNP (201773_at), because in at 
least one of the databases used, the previously used probe 
did not appear. In addition, as controls, we used ACTB 
(200801_x_at) and TUBA1B (211072_x_at). PYCARD 
(221666_s_at) and CASP1 (206011_at), two components 
of the inflammasome platform, were also analyzed. To 
analyze the possible connection between MAP17 and 
inflammatory diseases, we analyzed mRNA levels in three 
different databases: GSE52471 for psoriasis and discoid 
lupus [96], GSE13887 for lupus [97], and GSE20735 for a 
lupus model in mice [98]. To detect significant differences, 
Student’s t-test was applied for each pair of samples, with 
a significance threshold of p < 0.05.
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